GCN2 kinase activation by ATP-competitive kinase inhibitors

Mellinghoff I, Tang CP, Clark O, Ferrarone J, Campos C, Lalani AS, Chodera JD, Intlekofer AM, and Elemento O
Nature Chemical Biology}, 18:207, 2022 [DOI]

We describe paradoxical activation of GCN2 kinase activity by the kinase inhibitor neratinib, and propose a model for how inhibitor-induced dimerization might cause this unusual activity.

An open library of human kinase domain constructs for automated bacterial expression

Steven K. Albanese*, Daniel L. Parton*, Mehtap Isik**, Lucelenie Rodríguez-Laureano**, Sonya M. Hanson,  Julie M. Behr, Scott Gradia, Chris Jeans, Nicholas M. Levinson, Markus A. Seeliger, and John D. Chodera.
* co-first author; ** co-second author
Biochemistry 57:4675, 2018. [DOI] [PDF] [bioRxiv] [GitHub]
Interactive data browser: [github.io]
Plasmids available via AddGene

Human kinase catalytic domains---the therapeutic target of selective kinase inhibitors used in the treatment of cancer and other diseases---are notoriously difficult and expensive to express in insect or human cells. Here, we utilize the phosphatase co-expression technology developed by Markus Seeliger (now at Stony Brook) to develop a library of human kinase catalytic domains for facile and inexpensive expression in bacteria.

Ensembler: Enabling high-throughput molecular simulations at the superfamily scale

Daniel L. Parton, Patrick B. Grinaway, Sonya M. Hanson, Kyle A. Beauchamp, and John D. Chodera
PLoS Computational Biology 12:e1004728, 2016. [DOI] [PDF] [bioRxiv] / data: [Dryad] / code: [GitHub]

We demonstrate a new tool that enables---for the first time---massively parallel molecular simulation studies of biomolecular dynamics at the superfamily scale, illustrating its application to protein tyrosine kinases, an important class of drug targets in cancer.